These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 23794518

  • 1. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
    Zhu X, Wu L, Qiao H, Han T, Chen S, Liu X, Jiang R, Wei Y, Feng D, Zhang Y, Ma Y, Zhang S, Zhang J.
    J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H.
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
    Brady SW, Zhang J, Tsai MH, Yu D.
    Cancer Biol Ther; 2015 May; 16(3):402-11. PubMed ID: 25692408
    [Abstract] [Full Text] [Related]

  • 8. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.
    Clin Cancer Res; 2010 Mar 01; 16(5):1509-19. PubMed ID: 20179222
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
    Young CD, Arteaga CL, Cook RS.
    Breast Cancer Res; 2015 Dec 04; 17():148. PubMed ID: 26637440
    [Abstract] [Full Text] [Related]

  • 13. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS, Arnold SL, O'Regan RM, Nahta R.
    Anticancer Agents Med Chem; 2012 Feb 04; 12(2):151-62. PubMed ID: 22043997
    [Abstract] [Full Text] [Related]

  • 14. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M, Milano G, Formento P, Giacometti S, Denden A, Renée N, Iliadis A, Fischel JL, Ciccolini J.
    Fundam Clin Pharmacol; 2012 Aug 04; 26(4):530-7. PubMed ID: 21623901
    [Abstract] [Full Text] [Related]

  • 15. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY, Bang YJ.
    Cancer Lett; 2008 Dec 18; 272(2):296-306. PubMed ID: 18774637
    [Abstract] [Full Text] [Related]

  • 16. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May 18; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

  • 17. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S, Montero JC, Ocaña A, Pandiella A.
    J Natl Cancer Inst; 2010 Sep 22; 102(18):1432-46. PubMed ID: 20811002
    [Abstract] [Full Text] [Related]

  • 18. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ, Kolesar JM.
    Clin Ther; 2009 Sep 22; 31 Pt 2():2332-48. PubMed ID: 20110044
    [Abstract] [Full Text] [Related]

  • 19. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
    Chen S, Zhu X, Qiao H, Ye M, Lai X, Yu S, Ding L, Wen A, Zhang J.
    Tumour Biol; 2016 Feb 22; 37(2):2321-31. PubMed ID: 26369543
    [Abstract] [Full Text] [Related]

  • 20. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS.
    Mol Cancer Ther; 2016 Sep 22; 15(9):2198-208. PubMed ID: 27256378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.